Literature DB >> 19225277

Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.

Hiroyuki Uchida1, Shitij Kapur, Benoit H Mulsant, Ariel Graff-Guerrero, Bruce G Pollock, David C Mamo.   

Abstract

OBJECTIVE: It is generally held that the elderly are more sensitive to motor side effects of antipsychotics, although the mechanisms for such an effect are not fully understood. The objective of this study was to examine whether this sensitivity is due to a central pharmacokinetic (i.e., higher occupancy for a given plasma level) or pharmacodynamic (i.e., greater functional effects for a given occupancy) effect.
DESIGN: Cross-sectional.
SETTING: Centre for Addiction and Mental Health, Toronto, Ontario, Canada. PARTICIPANTS: Thirteen subjects aged 50 (mean +/- standard deviation age: 62 +/- 9 years) with schizophrenia or schizoaffective disorder who were receiving risperidone. MEASUREMENTS: Dopamine D2 binding potential in the striatum, using [C]raclopride positron emission tomography scan. D2 receptor occupancy was calculated, using age-corrected measure from healthy individuals and region of interest analysis.
RESULTS: The authors observed the expected nonlinear relationship between total risperidone and 9-hydroxyrisperidone plasma level and striatal D2 receptor occupancy. The estimated plasma level of risperidone plus 9-hydroxyrisperidone associated with 50% maximal receptor occupancy was 7.3 ng/mL, which is similar to what has been reported in younger patients. However, extrapyramidal side effects (EPS) were observed in seven subjects at D2 occupancy of 34%-79%, occupancy levels that are lower than previously reported for younger patients in whom EPS are rare at occupancies lower than 80%.
CONCLUSION: The observation of greater functional effect (EPS in this case) for a given drug occupancy than the younger patients supports a pharmacodynamic mechanism for age-related antipsychotic drug sensitivity. This finding has important implications for dosing of antipsychotics in older patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19225277     DOI: 10.1097/JGP.0b013e318198776d

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  17 in total

1.  Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.

Authors:  Hiroyuki Uchida; Takefumi Suzuki; Hiroyoshi Takeuchi; Tamara Arenovich; David C Mamo
Journal:  Schizophr Bull       Date:  2009-11-27       Impact factor: 9.306

Review 2.  A tipping point in drug dosing in late-life schizophrenia.

Authors:  Takashi Tsuboi; Takefumi Suzuki; Hiroyuki Uchida
Journal:  Curr Psychiatry Rep       Date:  2011-06       Impact factor: 5.285

3.  Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels.

Authors:  Gudrun Hefner; Mohamed E E Shams; Stefan Unterecker; Tanja Falter; Christoph Hiemke
Journal:  Psychopharmacology (Berl)       Date:  2015-06-03       Impact factor: 4.530

Review 4.  The effects of aging on insight into illness in schizophrenia: a review.

Authors:  Philip Gerretsen; Eric Plitman; Tarek K Rajji; Ariel Graff-Guerrero
Journal:  Int J Geriatr Psychiatry       Date:  2014-07-23       Impact factor: 3.485

5.  An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders.

Authors:  Thi Thu Ha Nguyen; Antoine Pariente; Jean-Louis Montastruc; Maryse Lapeyre-Mestre; Vanessa Rousseau; Olivier Rascol; Bernard Bégaud; François Montastruc
Journal:  Br J Clin Pharmacol       Date:  2016-11-06       Impact factor: 4.335

Review 6.  Management of schizophrenia in late life with antipsychotic medications: a qualitative review.

Authors:  Takefumi Suzuki; Gary Remington; Hiroyuki Uchida; Tarek K Rajji; Ariel Graff-Guerrero; David C Mamo
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

Review 7.  Sensitivity to antipsychotic drugs in older adults.

Authors:  Chloe Leon; Philip Gerretsen; Hiroyuki Uchida; Takefumi Suzuki; Tarek Rajji; David C Mamo
Journal:  Curr Psychiatry Rep       Date:  2010-02       Impact factor: 5.285

8.  Depression in the elderly: clinical features and risk factors.

Authors:  Gülfizar Sözeri-Varma
Journal:  Aging Dis       Date:  2012-10-21       Impact factor: 6.745

9.  Establishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people.

Authors:  Joel T Dunn; Chloe Clark-Papasavas; Paul Marsden; Stacey Baker; Marcel Cleij; Shitij Kapur; Robert Kessler; Robert Howard; Suzanne J Reeves
Journal:  J Cereb Blood Flow Metab       Date:  2013-04-17       Impact factor: 6.200

10.  Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

Authors:  Kazunari Yoshida; Robert R Bies; Takefumi Suzuki; Gary Remington; Bruce G Pollock; Yuya Mizuno; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Res       Date:  2014-02-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.